Health Care

Explore how Siemens Healthineers turns a €200 m tariff refund into AI‑powered imaging growth, cost‑control, and outcome‑based reimbursement gains.

UBS raises Sartorius AG preferred shares target to €300, citing strong growth, R&D pipeline and regulatory advantages—potential 10% upside in 12 months.

Fresenius’ €300m FMC share sale sharpens balance sheet, fuels growth in Fresenius Kabi and Helios, and boosts investor confidence in its focused healthcare strategy.

See how Bayer’s shares slipped on DAX’s muted rebound, driven by geopolitical tensions, energy costs, and tightening drug pricing—yet still showing solid financial resilience.

Merck KGaA boosts its flow‑cytometry edge with high‑parameter, spectral platforms and AI‑powered data science, positioning itself as a leader in precision diagnostics.

UnitedHealth Group’s Patrick Conway plans to sell 1,169 shares, a rule‑compliant insider move that expands float but won’t move the stock price.

Explore how Pfizer’s first‑half 2026 results show partnership-driven growth, milestone‑payment impact, and pipeline prospects amid margin pressure.

Johnson & Johnson’s resilient healthcare strategy blends high‑margin biologics, AI‑driven devices, and digital therapeutics to drive value‑based growth, outpacing peers amid rising rates and supply‑chain challenges.

Fresenius Medical Care’s €300 m stake sale sharpens its balance sheet, fuels R&D for next‑gen dialysis tech, and speeds regulatory approvals—boosting patient outcomes.

Danaher’s Rule 144 filing shows why its high‑precision medical devices keep hospitals ahead of reimbursement shifts, capital constraints, and workflow hurdles—delivering measurable cost savings and better patient outcomes.